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A SYSTEMATIC META-ANALYSIS OF CLINICAL TRIALS 
WITH DIACEREIN IN OSTEOARTHRITIS 
BF Leeb, B Rintelen 
Lower Austrian Centre for Rheumatology, Humanis Klinikum 
Stockerau, Stockerau, Austria 
Aim of Study: To compare the efficacy and safety of diacerein vs 
placebo or NSAIDs in hip or knee osteoarthritis (OA) patients. 
Methods: A literature search for randomised controlled trials 
(RCT) was performed using 3 databases. PubMed and Medline 
were searched using filter 10a while EMBASE was searched us- 
ing filter 5a. Unpublished study reports were also obtained. Study 
quality was rated by 2 independent assessors using the Jadad 
criteria (1996). Data extraction and double-data entry were per- 
formed. A detailed prospective statistical analysis plan was de- 
veloped under blind conditions using acknowledged standards for 
the extracted ata. 
Two study periods were analysed: the active treatment period and 
the treatment-free dechallenge period, if present. All studies were 
assessed for heterogeneity of the primary variables at baseline. 
Glass scores (standardised mean differences) were calculated 
and corrected for small sample size bias using the exact meth- 
ods. The inverse normal method was used for statistical assess- 
ment (significance level: p<0.05) of pooled results using exact 
weighting techniques. The results were assessed for robustness 
(sensitivity analysis) based on 3 different methods. Global alpha 
risk control was made using the Bonferroni-Holm procedure. The 
statistical analyses were based on the intention to treat principle 
as far as possible. 
The primary variables for the data extraction were pain (visual 
analogue scale); function (WOMAC or similar); intake of escape 
medication (analgesics or NSAIDs); global efficacy (subjective 
ratings by patients) and global safety (subjective ratings by pa- 
tients). 
Results: This meta-analysis was based on 19 RCTs with a to- 
tal of 2637 recruited patients. The mean Jadad score (0=poor; 
5= excellent) was 3.2. At the end of the active treatment period, 
diacerein showed a statistically significant greater reduction in 
pain, compared to placebo, and no significant difference versus 
NSAIDs. At the end of a dechallenge period (1-3 months), diac- 
erein showed a statistically significant superiority against placebo 
and NSAIDs for pain. 
For function (WOMAC or similar), diacerein showed a statistically 
significant superiority against placebo at the end of the active 
treatment period and a marked, but non-statistically significant 
superiority against NSAIDs. At the end of the dechallenge pe- 
riod, diacerein showed a statistically significant superiority versus 
placebo and NSAIDs. 
Escape medication intake was similar in all 3 groups at the end 
of active treatment. However, intake was statistically significantly 
lower in the diacerein group compared to the placebo and NSAID 
groups at the end of the dechallenge period. 
Global efficacy ratings showed a significant superiority of diac- 
erein vs placebo and NSAIDs at the end of the treatment phase. 
Global tolerability ratings showed a significant difference in favour 
of placebo and non-significant difference versus NSAIDs. 
Conclusions: This meta-analysis hows that diacerein is more 
effective than placebo and as effective as NSAIDs, during treat- 
ment and has a long carry over effect with a good safety profile 
compared to NSAIDs. 
P128 
QUADRICEPS FEMORIS MUSCLE RECOVERY AFTER 
TOTAL KNEE ARTHROPLASTY 
SC Petterson, L Snyder-Mackler 
Physical Therapy Department, University of Delaware, Newark, 
DE 
Aim: To determine the course of recovery of the quadriceps after 
total knee arthroplasty (TKA) and to understand the morphologi- 
cal and neural mechanisms contributing to long-term quadriceps 
strength outcomes. 
Methods: 41 patients were tested 94-5 days before primary, uni- 
lateral TKA and 274-3 days and 3 months after TKA and 16 pa- 
tients were tested 1 year after TKA. All patients completed 6 
weeks (average of 17 visits) of outpatient physical therapy fo- 
cusing on quadriceps strengthening. Quadriceps strength and 
muscle activation were measured using a burst superimposi- 
tion technique (a supramaximal burst of electrical stimulation is 
elicited during a maximal volitional isometric ontraction (MVlC)). 
MRI analysis was used to determine maximal quadriceps cross- 
sectional area (CSA). MR images were digitized and intramus- 
cular fat was removed using custom-written software (ICC=0.99). 
Two-way repeated measures ANOVA was used to determine dif- 
ferences in the measured quadriceps variables between limbs 
over time using paired t-tests for post hoc comparisons. Linear 
regression analysis was used to determine relative contributions 
to quadriceps trength. Alpha was set at p<0.05. 
Results: Significant differences between limbs and over time 
were found in quadriceps MVlC (F=138.87, p<0.001; F=51.83, 
p<0.001), activation (F=20.01, p<0.001; F=8.43, p<0.001), and 
CSA (F=58.86, p<0.001; F=13.46, p<0.001). The surgical limb 
had lower MVlC both before TKA (t=-5.53, p<0.001) and 1 (t=- 
13.59, p<0.001) and 3 (t=-18.57, p<0.001) months after TKA. 
The surgical limb had lower CSA both before TKA (t=-4.77, 
p<0.001) and 1 (t=-8.62, p<0.001) and 3 (t=-7.16, p<0.001) 
months after TKA. No differences in activation were evident be- 
fore TKA (t=-1.27, p=0.211) or at 3 (t=-1.85, p=0.07) months 
however, the surgical limb had lower activation 1 (t=-5.54, 
p<0.001) month post-TKA. One year after TKA, no significant 
differences were found between limbs in quadriceps MVlC (t=- 
0.33, p=0.747), CSA (t=-1.66, p=0.117), or activation (t=0.90, 
p=0.0.380). Together, activation and CSA explained 69% of the 
variance in involved quadriceps trength (R2=0.77, p<0.001 ) at 3 
months. When preoperative strength was added to the equation, 
77% of the variance in 3 month involved MVlC was explained. 
Activation and CSA explained 62% of the variance in involved 
quadriceps trength 1 year post-TKA (R2=0.62, p<0.05) however, 
preoperative strength was still the single strongest predictor of 1 
year involved strength (R2=0.72, p<0.001). 
Conclusions: Patients have deficits in muscle strength, activa- 
tion, and CSA 3 months after TKA, the time when the majority 
of patients are discharged from formal physical therapy. How- 
ever, full recovery of quadriceps muscle strength and morphol- 
ogy is evident 1 year postoperatively. While both inhibition and 
CSA contribute significantly to quadriceps weakness, preopera- 
tive strength is the best determinant of long-term strength out- 
comes. Delaying surgery until completely debilitated by pain, re- 
sulting in reduced function and quadriceps weakness, may limit 
full quadriceps recovery. Preoperative strengthening may opti- 
mize benefit from surgery. 
